RNA‐binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression

The androgen receptor (AR) pathway is critical for prostate cancer carcinogenesis and development; however, after 18‐24 months of AR blocking therapy, patients invariably progress to castration‐resistant prostate cancer (CRPC), which remains an urgent problem to be solved. Therefore, finding key mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jing, Zhang, Yu, Liu, Xi‐sheng, Zhu, Fang‐ming, Xie, Feng, Jiang, Chen‐yi, Zhang, Zi‐ye, Gao, Ying‐li, Wang, Yong‐chuan, Li, Bin, Xia, Shu‐jie, Han, Bang‐min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004550/
https://www.ncbi.nlm.nih.gov/pubmed/31833612
http://dx.doi.org/10.1111/cas.14280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004550/
https://www.ncbi.nlm.nih.gov/pubmed/31833612
http://dx.doi.org/10.1111/cas.14280

Ejemplares similares